BRPI0812816A2 - Derivados de sulfonil-quinolina - Google Patents

Derivados de sulfonil-quinolina

Info

Publication number: BRPI0812816A2
Authority: BR; Brazil
Prior art keywords: sulfonyl; quinoline derivatives; quinoline; derivatives
Prior art date: 2007-06-18

Application number

BRPI0812816-2A2A

Other languages

English (en)

Inventor

Janos Galambos

Gyoergy Keserue

Krisztina Gal

Monika Vastag

Amrita Agnes Bobok

Csaba Weber

Ibolya Prauda

Gabor Andras Wagner

Original Assignee

Richter Gedeon Nyrt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-18

Filing date

2008-06-17

Publication date

2014-12-23

2007-06-18 Priority claimed from HU0700417A external-priority patent/HU0700417D0/hu

2008-06-12 Priority claimed from HU0800376A external-priority patent/HUP0800376A2/hu

2008-06-17 Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt

2014-12-23 Publication of BRPI0812816A2 publication Critical patent/BRPI0812816A2/pt

2020-09-15 Publication of BRPI0812816B1 publication Critical patent/BRPI0812816B1/pt

2021-05-25 Publication of BRPI0812816B8 publication Critical patent/BRPI0812816B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Addiction (AREA)
Obesity (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)

BRPI0812816A 2007-06-18 2008-06-17 compostos derivados de sulfonil-quinolina, ligantes com preferência para subtipo de receptor mglur1 e mglur5, processos para a preparação dos referidos compostos, formulação farmacêutica compreendedo os referidos compostos e uso dos mesmos BRPI0812816B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
HU0700417A HU0700417D0 (en)	2007-06-18	2007-06-18	Sulfonyl-quinoline derivatives
HUP0700417		2007-06-18
HU0800376A HUP0800376A2 (en)	2008-06-12	2008-06-12	Sulfonyl-quinoline derivatives
HUP0800376		2008-06-12
PCT/HU2008/000068 WO2008155588A1 (en)	2007-06-18	2008-06-17	Sulfonyl-quinoline derivatives

Publications (3)

Publication Number	Publication Date
BRPI0812816A2 true BRPI0812816A2 (pt)	2014-12-23
BRPI0812816B1 BRPI0812816B1 (pt)	2020-09-15
BRPI0812816B8 BRPI0812816B8 (pt)	2021-05-25

Family

ID=89988338

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0812816A BRPI0812816B8 (pt)	2007-06-18	2008-06-17	compostos derivados de sulfonil-quinolina, ligantes com preferência para subtipo de receptor mglur1 e mglur5, processos para a preparação dos referidos compostos, formulação farmacêutica compreendedo os referidos compostos e uso dos mesmos

Country Status (27)

Country	Link
EP (1)	EP2167469B1 (pt)
JP (1)	JP5543917B2 (pt)
KR (1)	KR101532101B1 (pt)
CN (1)	CN101730684B (pt)
AU (1)	AU2008264999B8 (pt)
BR (1)	BRPI0812816B8 (pt)
CA (1)	CA2690079C (pt)
CO (1)	CO6311082A2 (pt)
CU (1)	CU23822A3 (pt)
CY (1)	CY1113251T1 (pt)
DK (1)	DK2167469T3 (pt)
EA (1)	EA016691B1 (pt)
EC (1)	ECSP109884A (pt)
ES (1)	ES2392905T3 (pt)
GE (1)	GEP20125524B (pt)
HR (1)	HRP20120877T1 (pt)
IL (1)	IL202463A (pt)
MX (1)	MX2009013959A (pt)
MY (1)	MY146992A (pt)
NI (1)	NI200900217A (pt)
NZ (1)	NZ581853A (pt)
PL (1)	PL2167469T3 (pt)
PT (1)	PT2167469E (pt)
RS (1)	RS52495B (pt)
SI (1)	SI2167469T1 (pt)
TN (1)	TN2009000511A1 (pt)
WO (1)	WO2008155588A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2751761A1 (en)	2008-10-22	2010-04-29	House Ear Institute	Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
CA2853923A1 (en) *	2011-11-03	2013-05-10	Merck Sharp & Dohme Corp.	Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use
RU2500672C1 (ru) *	2012-10-25	2013-12-10	Андрей Александрович Иващенко	(3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
AR106515A1 (es)	2015-10-29	2018-01-24	Bayer Cropscience Ag	Sililfenoxiheterociclos trisustituidos y análogos
US9932310B2 (en)	2016-02-08	2018-04-03	City Of Hope	DNA2 inhibitors for cancer treatment
KR101893515B1 (ko) *	2017-06-09	2018-08-30	영남대학교 산학협력단	구리 촉매를 이용한 4-하이드록시-3-설파닐쿠마린 유도체 또는 4-하이드록시-3-설파닐퀴놀리논 유도체의 신규 제조방법 및 이로 제조된 유도체 화합물과 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4038600A (en) *	1999-03-29	2000-10-16	Neurogen Corporation	4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
US6339093B1 (en) *	1999-10-08	2002-01-15	Hoffmann-La Roche Inc.	Isoquinoline derivatives
CA2421782A1 (en) *	2000-10-02	2002-04-11	Janssen Pharmaceutica N.V.	Quinoline and quinolinone derivatives as metabotropic glutamate receptor antagonists
US7452888B2 (en) *	2002-03-27	2008-11-18	Glaxo Group Limited	Quinoline derivatives and their use as 5-ht6 ligands
US20070027321A1 (en) *	2003-09-02	2007-02-01	Kamenecka Theodore M	Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
EP2284157A1 (en) *	2003-12-12	2011-02-16	Wyeth	Quinolines useful in treating cardiovascular disease
GB0519765D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
EA200801525A1 (ru) *	2005-12-20	2008-10-30	Рихтер Гедеон Нирт.	ПРОИЗВОДНЫЕ ХИНОЛИНА, ПРИМЕНИМЫЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ РЕЦЕПТОРАМИ mGluR5

2008
- 2008-06-17 EP EP08762671A patent/EP2167469B1/en active Active
- 2008-06-17 GE GEAP200811651A patent/GEP20125524B/en unknown
- 2008-06-17 WO PCT/HU2008/000068 patent/WO2008155588A1/en not_active Ceased
- 2008-06-17 KR KR1020097025394A patent/KR101532101B1/ko active Active
- 2008-06-17 RS RS20120457A patent/RS52495B/sr unknown
- 2008-06-17 CN CN2008800207550A patent/CN101730684B/zh active Active
- 2008-06-17 HR HRP20120877AT patent/HRP20120877T1/hr unknown
- 2008-06-17 PL PL08762671T patent/PL2167469T3/pl unknown
- 2008-06-17 EA EA201070025A patent/EA016691B1/ru unknown
- 2008-06-17 DK DK08762671.9T patent/DK2167469T3/da active
- 2008-06-17 MX MX2009013959A patent/MX2009013959A/es active IP Right Grant
- 2008-06-17 JP JP2010512781A patent/JP5543917B2/ja active Active
- 2008-06-17 CA CA2690079A patent/CA2690079C/en active Active
- 2008-06-17 AU AU2008264999A patent/AU2008264999B8/en active Active
- 2008-06-17 PT PT08762671T patent/PT2167469E/pt unknown
- 2008-06-17 MY MYPI20095244A patent/MY146992A/en unknown
- 2008-06-17 NZ NZ581853A patent/NZ581853A/xx unknown
- 2008-06-17 SI SI200830764T patent/SI2167469T1/sl unknown
- 2008-06-17 BR BRPI0812816A patent/BRPI0812816B8/pt active IP Right Grant
- 2008-06-17 ES ES08762671T patent/ES2392905T3/es active Active
2009
- 2009-12-02 IL IL202463A patent/IL202463A/en active IP Right Grant
- 2009-12-09 TN TNP2009000511A patent/TN2009000511A1/fr unknown
- 2009-12-15 NI NI200900217A patent/NI200900217A/es unknown
- 2009-12-16 CU CU20090219A patent/CU23822A3/es active IP Right Grant
2010
- 2010-01-15 CO CO10003762A patent/CO6311082A2/es active IP Right Grant
- 2010-01-18 EC EC2010009884A patent/ECSP109884A/es unknown
2012
- 2012-10-25 CY CY20121101007T patent/CY1113251T1/el unknown

Also Published As

Publication number	Publication date
IL202463A (en)	2013-08-29
BRPI0812816B1 (pt)	2020-09-15
CU23822A3 (es)	2012-06-21
MX2009013959A (es)	2010-03-09
AU2008264999A1 (en)	2008-12-24
DK2167469T3 (da)	2012-11-12
JP2010530407A (ja)	2010-09-09
PL2167469T3 (pl)	2013-01-31
EP2167469B1 (en)	2012-08-15
SI2167469T1 (sl)	2012-10-30
CA2690079A1 (en)	2008-12-24
AU2008264999B8 (en)	2013-10-31
CN101730684A (zh)	2010-06-09
EA201070025A1 (ru)	2010-04-30
PT2167469E (pt)	2012-11-20
WO2008155588A1 (en)	2008-12-24
TN2009000511A1 (en)	2011-03-31
MY146992A (en)	2012-10-15
CU20090219A7 (es)	2011-10-14
CA2690079C (en)	2016-01-26
IL202463A0 (en)	2010-06-30
EP2167469A1 (en)	2010-03-31
JP5543917B2 (ja)	2014-07-09
WO2008155588A8 (en)	2009-12-30
ECSP109884A (es)	2010-02-26
CO6311082A2 (es)	2011-08-22
KR101532101B1 (ko)	2015-06-26
BRPI0812816B8 (pt)	2021-05-25
CN101730684B (zh)	2013-07-24
NI200900217A (es)	2010-10-04
RS52495B (sr)	2013-02-28
NZ581853A (en)	2012-11-30
KR20100021434A (ko)	2010-02-24
GEP20125524B (en)	2012-05-25
AU2008264999B2 (en)	2013-09-26
HK1141009A1 (en)	2010-10-29
EA016691B1 (ru)	2012-06-29
HRP20120877T1 (hr)	2012-11-30
ES2392905T3 (es)	2012-12-14
CY1113251T1 (el)	2016-04-13

Publication	Publication Date	Title
FR24C1047I2 (fr)	2025-10-10	Derive de 4-pyrimidinesulfamide
BRPI0813707A2 (pt)	2014-12-30	Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt)	2015-05-05	Derivados de isoxazol-piridina
BRPI0809992A2 (pt)	2014-10-14	Derivados de pirrolopirimidina
BRPI0820113A2 (pt)	2015-05-05	Derivados de isoxazolo-piridazina
BRPI0812155A2 (pt)	2019-09-24	derivados de espiroindolinona
BRPI0817935A2 (pt)	2015-04-07	Derivados de biarila
DK2209786T3 (da)	2013-06-03	Pyrimidinsubstituerede purinderivater
EP2226315A4 (en)	2012-01-25	2-aminoquinazoline DERIVATIVE
BRPI0813836A2 (pt)	2015-01-06	Derivados pirazólicos
BRPI0812518A2 (pt)	2015-03-31	Derivados de indazolamida
BRPI0814236A2 (pt)	2015-01-06	Derivados de quinazolinamida
BRPI0820649A2 (pt)	2015-06-16	Derivados de isoxazalo-pirazina
ATE475662T1 (de)	2010-08-15	Dihydropyrazolopyrimidinonderivate
ATE483711T1 (de)	2010-10-15	Spiroindolinonderivate
ATE469905T1 (de)	2010-06-15	Pyridopyrimidinonderivate
DK2308877T3 (da)	2014-04-22	Imidazopyridin-2-on-derivater
ATE512135T1 (de)	2011-06-15	Spiroindolinonderivate
BRPI0915064A2 (pt)	2015-10-27	derivados de qunoxalinadiona
DK2035394T3 (da)	2009-10-05	2-pyrazincarboxamidderivater
BRPI0913832A2 (pt)	2015-10-20	derivados de pirrolopiridinilpirimidin-2-ilamina
DK2152370T3 (da)	2011-08-15	Aryletherpyridazinonderivater
DK2275414T3 (da)	2015-06-22	Cyclopentylacrylamidderivat
ATE544764T1 (de)	2012-02-15	5-hydroxymethyloxazolidin-2-onderivate
BRPI0913234A2 (pt)	2016-01-19	derivados de tiazolilpiperidina

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-16	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-12-03	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-03-17	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-07-14	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-09-15	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF